.
.
.eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.
http://lm360.us/Swartzlander-son-of-Sosebee-from-Mitsugoe?Rathgebne=230 ai-based software may help predict risk of dementia
.
.
. 0 comments
. ?????